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Abstract
Background: Our purpose was to examine the reliability and validity of the Chinese version of the Patient Health
Questionnaire-15 (PHQ-15) in Taiwan, and to explore its relation to somatoform disorders (DSM-IV) and to somatic
symptom and related disorders (DSM-5).
Methods: We recruited 471 individuals, 151 with somatoform disorders and 200 with somatic symptom and related
disorders. Subjects completed the Chinese version of the PHQ-15, Beck Depression Inventory-II (BDI-II), Beck Anxiety
Inventory (BAI), and received a DSM-IV- and DSM-5-based diagnostic interview. We performed exploratory factor
analysis and assessed test-retest reliability, internal consistency, and correlation with BDI-II/BAI to confirm reliability and
validity, and carried out ROC curve analysis to determine suitability for evaluation or screening purposes. PHQ-15 scores
were compared between patients with various DSM-IV psychiatric diagnoses (such as DSM-IV somatoform disorders,
panic disorder, other anxiety/depressive disorders) or no DSM-IV diagnosis and patients with DSM-5 somatic symptom
and related disorders or no DSM-5 diagnosis.
Results: The Chinese version identified cardiopulmonary, pain-fatigue, and gastrointestinal as major factors and had
good reliability (0.803–0.930), internal consistency (0.637–0.861), and correlation coefficients with BDI-II/BAI (0.407–0.619,
0.536–0.721, respectively). The PHQ-15 scores were similar in patients with somatoform disorders and patients with
panic disorder; higher in patients with somatoform disorders and panic disorder than in patients with other anxiety/
depressive disorders; and significantly higher in patients with somatic symptom and related disorders than in patients
without this diagnosis. The AUC of the PHQ-15 was 0.678 (cutoff 6/7) for screening somatoform disorders (DSM-IV) and
0.725 (cutoff 4/5) for screening somatic symptom and related disorders (DSM-5).
Conclusions: The Chinese version of the PHQ-15 is suitable for evaluating somatic symptom and related disorders. The
preponderance of somatic symptom disorder in our sample, lack of evaluation of functional disorders, and recruitment
solely from psychiatric clinics are possible limitations.
Keywords: Patient Health Questionnaire-15, Somatoform disorders, Somatic symptom and related disorders, Somatic
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Highlights
1. The Chinese version of PHQ-15 focuses on 3
major factors.
2. Its validity and reliability are satisfactory.
3. The AUC of the PHQ-15 is higher for screening
somatic symptom and related disorders than for
screening somatoform disorders.
Background
Psychiatric disorders presenting with mainly somatic
symptoms are described in the Diagnostic and Statistical
Manual of Mental Disorders (DSM) and International
Classification of Diseases (ICD). Although the gold
standard method for diagnosing a DSM or ICD psychi-
atric disorder is the diagnostic interview, it is hard to
interview all subjects in large-scale epidemiological stud-
ies. Therefore, it is clinically important to determine
whether self-administered psychometric tools plus diag-
nostic criteria can be used for screening or evaluating
the severity of this group of disorders. Some of these
tools include the World Health Organization Schedule
for Somatoform Disorders Screener, the Symptom
Checklist-12, and the widely used Patient Health
Questionnaire-15 (PHQ-15) [1]. Developed by Kroenke
et al., the PHQ-15 is the self-administered version of the
Primary Care Evaluation of Mental Disorders (PRIME-
MD) [1, 2]. Differing from the depression-oriented
Patient Health Questionnaire-9 (PHQ-9), the PHQ-15 is
focused on somatic distress. It contains 15 items rated
on a 3-point Likert scale (ranging from 0 [not bothered
at all] to 2 [bothered a lot]) [1]. Many studies have
shown that the PHQ-15 has good content validity and
reliability [3–6], and is suitable for screening or evaluat-
ing somatoform disorders defined by the DSM-IV [7–9].
One of the changes from the DSM-IV to the DSM-5 is
in the concept of somatic symptoms. The “somatoform
disorders” have become “somatic symptom and related
disorders”. Whereas the emphasis of the DSM-IV is on
“medically unexplained,” that of the DSM-5 is on the “dis-
tress” of somatic discomforts [10]. Because the term
“medically unexplained” reflects the absence of clear diag-
nosis, this change of emphasis in the DSM-5 may increase
not only diagnostic consistency, but also the size of this
group of disorders. Though developed in the DSM-IV era,
the 15 items of the PHQ-15 do not specifically ask about
“medically unexplained” symptoms [1]. Therefore, it may
also be used to evaluate somatic symptom and related
disorders in the DSM-5. Evidence shows the applicability
of the PHQ-15 to evaluation of somatic symptom disorder
as defined by the DSM-5 [11]. In a systematic review, the
PHQ-15 was the most psychometrically valid and useful
of all somatic symptom questionnaires [12]. Moreover, the
PHQ-15 has also been used in studies of functional
disorders (such as fibromyalgia, irritable bowel syndrome,
chronic pelvic pain) [13–19], other psychiatric disorders
(such as depressive disorder and anxiety disorder)
[20–23], and physical diseases (such as benign pros-
tate hypertrophy) [24, 25].
The PHQ-15 has been translated into many lan-
guages. The Korean version (which is reported to
have good reliability and content validity [4] was used
to explore the relation between somatic and depres-
sive symptoms [26]. The Chinese version had satisfac-
tory internal consistency and test-retest reliability in a
Hong Kong population [27]. High score on the PHQ-
15 was shown to be associated with female gender,
young age, low educational level, and low economic
status [27]. Studies in China show that somatization
(as defined by the PHQ-15) is highly associated with
depression and anxiety [28] and that a cutoff of 10
points is suitable for the detection of somatizers [29].
Even though the PHQ-15 has yet to be applied in
Taiwan, we consider it a suitable tool for evaluating
somatic symptoms in Taiwan. Because the description
of somatic symptoms varies between China, Hong
Kong, and Taiwan, a Chinese version of the PHQ-15
is needed specifically for the population in Taiwan.
For exploring the above issues, we translated the
PHQ-15 into Taiwanese Mandarin (Traditional Chinese
Mandarin that includes Taiwanese vocabulary) and
applied it to our investigation of somatic symptoms in
Taiwan. The 3 aims of our present study were to 1)
determine the content reliability and validity of the
Chinese version of the PHQ-15; 2) clarify the relation-
ships among different types of somatic symptoms in the
Taiwanese population; and 3) investigate whether the
PHQ-15 is suitable for screening purposes and for evalu-
ating the severity of somatoform disorders (DSM-IV)
and somatic symptom and related disorders (DSM-5).
Methods
Participants and procedure
This study was performed after getting the approval of
Institutional Review Board of National Taiwan University
Hospital. We recruited subjects from 2 sites: National
Taiwan University Hospital (which is located in an urban
region of Taiwan) and National Taiwan University Hospital,
Yun-Lin Branch (which is in a rural area of Taiwan). Indi-
viduals were recruited from the psychiatric outpatient
clinics and communities near the 2 hospitals. Our study
targets were: (1) patients with depression, anxiety, or
somatic symptoms followed in psychiatric clinics; (2)
healthy subjects without physical or psychiatric illnesses.
Exclusion criteria were: (1) having psychotic symptoms or
reality disturbance; (2) having cognitive impairment or diffi-
culty reading questionnaires; (3) age lower than 15 or
higher than 70 years old (parents of subjects lower than
Liao et al. BMC Psychiatry  (2016) 16:351 Page 2 of 8
20 years old completed parental consents); (4) having a life-
threatening physical disease. After completing the informed
consent form, the individuals received a diagnostic inter-
view and completed the Chinese version of the PHQ-15,
Beck Depression Inventory-II (BDI-II), and Beck Anxiety
Inventory (BAI). Other demographic factors were recorded
by research assistants. To assess test-retest reliability, some
subjects completed the PHQ-15 again 2 weeks later.
Construction of psychiatric diagnoses
Clinical interview was performed by 4 board-certified
psychiatrists. The interview was conducted in 3 parts.
The first part focused on somatoform disorders of the
DSM-IV-TR and used the Structured Clinical Interview
for DSM-IV Axis I Disorders (SCID-1), Module G, to
ensure consistency. The second part examined all DSM-
IV-TR diagnoses other than somatoform disorders. The
third part was solely about somatic symptom and related
disorders in the DSM-5. Because the structured inter-
view does not cover DSM-5 diagnoses, this part was
based on the criteria for somatic symptom disorder
(SSD) including the existence of 1 or more distressing
somatic symptoms (SSD criterion A); having cognitive,
emotional or behavioral features such as catastrophizing
cognitive style, persistent high level of health anxiety, or
abnormal illness behavior related to somatic symptoms
(SSD criterion B); and presence of the above symptoms
for at least 6 months (SSD criterion C).
The translation of the Chinese version of the patient
health questionnaire-15
The authors of the original version of the PHQ-15 were
contacted and agreed to this translation. The translation
was performed in 3 steps. Firstly, a psychiatric specialist
translated the English version of the PHQ-15 into
traditional Chinese but using a vocabulary common in
Taiwan. Secondly, 2 specialists in psychosomatics checked
and modified the Chinese version. Finally, a backward
translation was performed by another specialist to confirm
consistency.
Other psychometric measurements
The Beck Depression Inventory-II (BDI-II), a 21-
question self-administered questionnaire, developed by
Aaron T. Beck in 1996 [30], with items evaluated on a
4-point Likert scale (0 for not at all to 3 for severely)
can be used for individuals older than 13 years. Individ-
uals are asked to rate their mood status 2 weeks before
the assessment. The BDI-II has been proven to have
good content validity and reliability and excellent test-
retest reliability and internal consistency (i.e., 0.93 and
0.91, respectively) [30]. Summated scores of 14–19, 20–
28, and 29–63 indicate mild, moderate, and severe de-
pression, respectively. The content validity and reliability
of the Chinese version of the BDI-II (used in our study)
was previously assessed by [31]. Internal consistency of
BDI-II in our sample was 0.94.
The Beck Anxiety Inventory (BAI) [32] is similar to the
BDI-II; is a self-administered questionnaire consisting of
21 4-point Likert scale items (rated 0 for not at all to 3 for
severely); is suitable for individuals aged 17–80 years, and
emphasizes the somatic aspects of anxiety (panic-like).
Individuals answer the questions based on their current
feelings. It has good test-retest reliability of 0.75, good
internal consistency of 0.85, and moderate correlation
with BDI-II, STAI-state, and STAI-trait (0.66, 0.47, 0.58,
respectively) [30, 33]. The cutoffs of the BAI are 8, 16, and
26 points. The Chinese version of the BAI used in our
study also had good content reliability and validity [34].
Its internal consistency in our sample was 0.95.
Statistical analysis
SPSS (version 19) and LISREL (version 8.51) were used for
statistical analysis. We used the Shapiro-Wilk test on all
continuous variable data at first. If the result was not
compatible with a normal distribution, a non-parametric
method would be adopted in further steps. Using the PHQ-
15 data of all subjects, exploratory factor analysis (with
principal component analysis for extraction and varimax
for factor rotation) was performed to clarify the relationship
among items. A specific latent structure described by
Kroenke et al. [2] was then examined with confirmatory
factor analysis. The test-retest reliability (using the intra-
class correlation coefficient) and internal consistency (using
Cronbach’s alpha) of PHQ-15 total scores and 3 major
factors identified in exploratory factor analysis were
assessed. The associations of PHQ-15 total scores, PHQ-15
major factor scores, BDI-II score, and BAI score were
evaluated using Pearson’s correlation analysis.
The results of the diagnostic interview were used to
analyze the relation between the PHQ-15 and clinical diag-
noses. Based on the DSM-IV-TR, subjects were divided into
a panic disorder group, somatoform disorders group, other
neurotic disorders group, and others without psychiatric
diagnoses group. ANOVA (with post-hoc analysis using the
Scheffé method) was performed to compare the PHQ-15
scores of the 4 groups. ROC curve analysis was used to
determine the optimal cutoff value of the PHQ-15 score for
somatoform disorders. Based on the DSM-5, subjects were
divided into groups with/without somatic symptom and
related disorders, and an independent t test was used to
compare PHQ-15 scores between these groups. Finally, cut-
offs for different severities (mild, moderate, and severe) of
SSD (the most common diagnosis in our subjects with
somatic symptom and related disorders) were determined
from the ROC curve. An ROC curve was used because
SSD can be defined in terms of severity, and different sever-
ities can be viewed as categorical variables.
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Results
Demographic data and psychiatric diagnoses of the
sample
Among the 471 subjects who entered this study, 292 had at
least one DSM-IV-TR diagnosis, 151 had somatoform dis-
orders (defined by DSM-IV-TR), and 200 had somatic
symptom and related disorders (defined by DSM-5). All
had a mean age of 44.68 (SD 13.82) years; mean BMI of
23.25 (SD 3.94) kg/m2; and mean duration of psychiatric ill-
ness of 2.05 (SD 4.10) years. Moreover, there were 172 male
subjects (37.15 %), 187 (39.70 %) who lived in urban areas,
and 267 (56.69 %) who were married. The mean PHQ-15,
BDI-II, and BAI scores were 7.54 (SD 5.73), 14.54 (SD
12.55), and 13.36 (SD 12.67), respectively.
The DSM-IV-TR category of somatoform disorders (n =
151) included undifferentiated somatoform disorder (n =
126), pain disorder (n = 19), and hypochondriasis (n = 16).
The main diagnoses other than somatoform disorders
were major depressive disorder (n = 108), generalized anx-
iety disorder (n = 59), panic disorder (n = 56), adjustment
disorder (n = 21), dysthymic disorder (n = 20), and mixed
depressive and anxiety disorder (n = 17). No patients were
comorbid with panic disorder and somatoform disorders
(as defined by DSM-IV-TR). The most common comor-
bidities for somatoform disorders and panic disorder were
both major depressive disorder (comorbid with somato-
form disorders, n = 67; with panic disorder, n = 9) and
generalized anxiety disorder (comorbid with somatoform
disorders, n = 37; with panic disorder, n = 7).
Among the 200 individuals with somatic symptom and
related disorders (DSM-5), most had somatic symptom
disorder (n = 190), 6 had illness anxiety disorder (with
most DSM-IV hypochondriasis subjects diagnosed as
having DSM-5 somatic symptom disorder), and 4 had
psychological factors affecting their medical conditions.
Reliability and validity
The results of exploratory factor analysis are shown in
Table 1. Four major factors (cardiopulmonary [factor 1],
pain-fatigue [factor 2], gastrointestinal [factor 3], dysmenor-
rhea [factor 4]) were identified. However, factor 4 consisted
of only 1 item (item 4), so item 4 was excluded from further
analysis (note-it was also excluded from the analyses of
Kroenke et al. and others [2, 35]). The loadings of items 11,
10, 7, and 9 on factor 1 were 0.661–0.799; items 3, 2, 6, 8,
14, and 15 on factor 2 were 0.524–0.799; and items 13, 1,
12, and 5 on factor 3 were 0.428–0.715. Additional file 1:
Table S1 reveals the results of confirmatory factor analysis.
The analysis supports the slightly better performance of
our 3-factor model than the original 3-factor model by
Kroenke et al. [2]. The test-retest reliability of the PHQ-15
total, factor 1, factor 2, and factor 3 was 0.930, 0.928, 0.803,
and 0.911, respectively, and the internal consistency was
0.861, 0.811, 0.781, and 0.637. Among the 3 factors, test-
retest reliability of factor 2 was a little lower than that of
factor 3 while the internal consistency of factor 3 was a
little lower than that of factor 2.
The correlations between PHQ-15 and BDI-II and
BAI were moderate to high (Table 2). The correlation
coefficient between the PHQ-15 total score and BAI
score was 0.721, and between the PHQ-15 total score
and BDI-II score was 0.619. The inter-correlations and









PHQ11: Shortness of breath 0.799
PHQ10: Palpitation 0.738
PHQ07: Chest pain 0.709
PHQ09: Fainting spells 0.661
PHQ03: Pain in extremities 0.689
PHQ02: Back pain 0.662
PHQ06: Headache 0.638
PHQ08: Dizziness 0.603
PHQ14: Sleep disturbance 0.594
PHQ15: Fatigue 0.524 0.520
PHQ13: Nausea or indigestion 0.715
PHQ01: Stomach pain 0.651
PHQ12: Constipation or diarrhea 0.612
PHQ05: Sexual problems 0.428
PHQ04: Menstrual cramps 0.822
Items with factor loading <0.4 were excluded
PHQ-15 Patient Health Questionnaire-15
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correlations of the 3 major factors of the PHQ-15 with
BDI-II and BAI ranged from 0.4 to 0.7.
The relation with DSM-IV diagnoses
Based on the DSM-IV-TR, subjects were divided into a
somatoform disorders group, panic disorder group (with-
out any somatoform diagnosis), other neurosis group, and
no psychiatric diagnosis group. Table 3 compares the
PHQ-15 scores in the 4 groups. PHQ-15 scores were a
little (though not statistically) higher in the panic disorder
group than the somatoform disorders group and signifi-
cantly higher in the above 2 groups than in the other
neurosis group and no psychiatric diagnosis group.
The result of ROC curve analysis to assess the accur-
acy of somatoform disorders detection with the PHQ-15
is shown in Table 4 and Additional file 2: Figure S1. The
AUC was 0.678 and the optimal cutoff was 6/7 (You-
den’s index 0.269). At this cut point, the sensitivity-
specificity sum was the highest (1.27).
The relation with DSM-5 diagnoses
The comparison of PHQ-15 scores between 2 groups of
individuals (1 with and 1 without somatic symptom and
related disorders [DSM-5]) is shown in Table 3. The
somatic symptom and related disorders group actually
had a higher PHQ-15 score (those with the diagnosis:
mean = 10.04; those without the diagnosis: mean = 5.69).
The ROC curve of the PHQ-15 item scores for detecting
somatic symptom and related disorders is also shown in
Table 4 and Additional file 2: Figure S1. The AUC (0.725)
was higher than that determined for somatoform disor-
ders (DSM-IV-TR). Similarly the cutoff (4/5) and Youden’s
index (0.332) were higher than those determined for the
DSM-5 diagnosis.
Because most subjects with somatic symptom and
related disorders in our study had SSD (which can be
categorized as mild, moderate, or severe according to
DSM-5 criteria), ROC curve analysis was performed
again to determine the cutoffs for somatic symptom
disorder of different severity (AUCs and Youden’s
indexes are shown in Table 4). The optimal cutoffs were
4/5, 6/7, and 12/13 for mild, moderate, and severe
disease, respectively.
Discussion
Our study had 4 main findings. First, cardiopulmonary,
pain-fatigue, and gastrointestinal are the major factors in
the Chinese version of the PHQ-15. Second, the Chinese
version of the PHQ-15 shows good reliability, and PHQ-15
score shows moderate correlation with BAI and BDI-II
scores. Third, the Chinese version of the PHQ-15 cannot
distinguish the DSM-IV-TR diagnosis of somatoform disor-
ders from that of panic disorder. Fourth, the Chinese
version of the PHQ-15 (cutoff point of 4/5) can be used to
screen for somatic symptom and related disorders (DSM-
5). These findings support our hypothesis that the PHQ-15
can be used to evaluate somatic symptom and related disor-
ders (DSM-5) in Taiwan.
Three major factors were identified by exploratory factor
analysis. Factor 1 included items 11 (shortness of breath),
10 (palpitation), 7 (chest pain), and 9 (fainting spells),
which are features of mainly cardiopulmonary disease and
panic attack. Therefore, it was designated the cardiopul-
monary factor. Factor 2 consisted of items 3 (pain in








PHQ-15 total 0.814 0.911 0.777 0.619 0.721
Factor 1 (Cardiopulmonary) 0.614 0.505 0.515 0.647
Factor 2 (Pain-fatigue) 0.589 0.604 0.658
Factor 3 (Gastrointestinal) 0.407 0.536
BDI-II 0.706
All p values are < 0.001
PHQ-15 Patient Health Questionnaire-15, BDI-II Beck Depression Inventory-II, BAI Beck Anxiety Inventory
Table 3 Comparison of the PHQ-15 in subjects with different DSM-IV/DSM-5 diagnosis
DSM-IV Somatoform disorders
(S, n = 151)
Panic disorder
(P, n = 56)
Other neurotic disorders
(O, n = 85)
No psychiatric disorder
(N, n = 179)
Statistics
mean (±SD) mean (±SD) mean (±SD) mean (±SD) F p value Comparison
PHQ-15 total 9.85 (±5.98) 10.96 (±6.18) 7.42 (±4.67) 4.56 (±4.15) 38.318 <0.001 S, P > O > N
DSM-5 With somatic symptom and
related disorders (n = 200)
Without somatic symptom and
related disorders (n = 271)
Statistics
mean (±SD) mean (±SD) t p value
PHQ-15 total 10.04 (±6.03) 5.69 (±4.72) –8.789 <0.001
PHQ-15 Patient Health Questionnaire-15
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extremities), 2 (back pain), 6 (headache), 8 (dizziness), 14
(sleep disturbance), and 15 (fatigue), which deal with pain,
neurological symptoms, and fatigue; so it was designated
the pain-fatigue factor. Phenomenologically, these symp-
toms are associated with fibromyalgia and chronic fatigue
syndrome. Factor 3 included items 13 (nausea due to indi-
gestion), 1 (stomach ache), 12 (constipation or diarrhea),
and 5 (sexual problems). Because of its association with
the digestive system and irritable bowel syndrome, factor
3 was designated the gastrointestinal factor. Notably,
sexual problems belonged to factor 3, and item 4 (men-
strual cramps) was an independent factor. After removing
item 4 (which is also removed in Kroenke et al.’s original
3-factor model), the discriminant validity of item 15
increased. Previous studies of the structure of the PHQ-15
revealed the existence of 1 − 5 factors (e.g., 4 factors [car-
diopulmonary, gastrointestinal, pain, and neurological] by
the Hong Kong study [27] and 1 bifactor [35] [1 general
factor and 4 specific symptom factors]). The differences
may be attributed to cultural and sample source differences
(e.g., if more subjects have panic disorder, the cardiopulmo-
nary factor may be more prominent). Our results also indi-
cate a possible overlap between fibromyalgia and chronic
fatigue syndrome in Taiwan. This phenomenon warrants
further exploration. In our sample, our 3-factor model
shows better model fit than the original 3-factor model by
Kroenke et al. (Additional file 1: Table S1) [2]. It might be
explained by cross-cultural differences (e.g., in Taiwan,
dizziness is highly associated with fatigue and pain as noted
in another Chinese study) [36].
In our sample, internal consistency and test-retest
reliability of PHQ-15 total scores were good and
similar to those found in previous reliability studies [4,
6, 27, 37–39]. The PHQ-15 total score and the 3 main
factor scores show moderate to high correlation with
BDI-II and BAI scores. Many studies have found that
somatization is often comorbid with depression and
anxiety [20, 40–42] and may explain why the correl-
ation between the PHQ-15, BDI-II, and BAI is not
low. Additionally, among self-administered anxiety
questionnaires, the BAI places more emphasis on
somatic symptoms, which is compatible with the high
correlation between the PHQ-15 and BAI scores.
From the above, we consider that the Chinese version
of PHQ-15 is both valid and reliable.
From the standpoint of the DSM-IV-TR, PHQ-15
score cannot distinguish somatoform disorders from
panic disorder, with the cardiopulmonary factor being
identified by factor analysis as the main contributor to
panic disorder. However, the PHQ-15 can still be used
to discriminate between panic/somatoform disorders
and other neurosis. The suitable cutoff for somatoform
disorders was 6/7 and differs from 2/3, 4/5, 8/9, and 9/
10 reported in other studies [1, 7, 8, 43, 44]. Although
our results are compatible with previous findings, the
impact of panic disorder on the PHQ-15 should be
assessed carefully in the context of the DSM-IV-TR.
PHQ-15 scores differed significantly between the group
with and the group without somatic symptom disorder
(DSM-5). The AUC of the PHQ-15 for screening somatic
symptom and related disorders was higher than that for
screening somatoform disorders (0.725 vs 0.678). This may
be explained by the emphasis on somatic distress in the
DSM-5, which leads to panic disorder and somatic symp-
tom and related disorders becoming more common comor-
bidities. It differs from the rationale used in differentiating
between DSM-IV-TR diagnoses. The reduction in optimal
cutoff to 4/5 can also be attributed to the comorbidity of
panic disorder and somatic symptom and related disorders.
Accordingly, we think that PHQ-15 is more suitably applied
in the DSM-5 context. Our results also indicate that the
PHQ-15 with cutoffs 4/5, 6/7, and 12/13 can be used to
assess somatic symptom disorder severity. The sensitivity
was higher than the specificity for the first 2 cutpoints; the
specificity was higher for the last cutpoint. However, PHQ-
15 is not designed to detect SSD specifically and has no
question items about SSD criterion B. Some recently devel-
oped questionnaires may be more helpful for exploring
SSD criterion B, such as the Somatic Symptom Disorder-B
Criteria Scale (SSD-12) [45].
The present study has several limitations. First, a huge
proportion in our sample had undifferentiated somato-
form disorder in DSM-IV-TR (or somatic symptom
disorder in DSM-5). Though somatic symptom disorder
Table 4 Cutoffs for somatoform disorders in the DSM-IV, somatic symptom and related disorders in DSM-5, and somatic symptom











Cutoff of the PHQ-15 total 6/7 4/5 4/5 6/7 12/13
Sensitivity 0.669 0.845 0.847 0.839 0.571
Specificity 0.600 0.487 0.477 0.384 0.721
Youden’s index 0.269 0.332 0.324 0.223 0.292
AUC 0.678 0.725 0.718 0.597 0.598
AUC area under the curve of receiver operating characteristic
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is the prototype of this category in DSM-5, whether the
Chinese version of the PHQ-15 can be used to assess
other disorders with somatic symptoms (such as illness
anxiety disorder or conversion) still awaits clarification.
Second, we did not directly assess functional disorders
not defined by psychiatrists (such as chronic fatigue
syndrome, fibromyalgia, and irritable bowel syndrome).
Therefore, our inferences from this analysis are partially
speculative and should be examined in the future. Third,
our study sample consisted of psychiatric patients and
healthy individuals in communities. But patients followed
only in the clinics of other specialists were not enrolled.
Because some patients with functional disorders do not
visit psychiatrists, our sample may not be representative of
individuals with somatic distress. Inclusion of these
patients in future investigations may increase our under-
standing of the application of the PHQ-15. Fourth, since
the cardiopulmonary factor is the main panic disorder-
related and anxiety disorder-related subdomain in the
PHQ-15, PHQ-15 does not seem to be a specific tool for
somatic symptom and related disorders. Finally, we did
not examine the inter-rater reliability for the DSM-5-
based diagnostic interview.
Conclusions
Our results support the hypothesis that the Chinese
version of PHQ-15 is applicable in Taiwan. The PHQ-15 is
more suitable to use in assessing somatic symptom and
related disorders (DSM-5) than somatoform disorders
(DSM-IV). We believe that this tool will be helpful in
screening, evaluating the severity of somatic symptoms,
and evaluating the treatment response of patients with
somatic symptoms in Taiwan. From a research perspective,
we expect to find associations of physiological or psycho-
logical indices with the PHQ-15 score that increase our
understanding of somatic distress. The relationship
between some functional disorders not defined by psychia-
trists and the PHQ-15 is also worthy of investigation.
Additional files
Additional file 1: Table S1. Confirmatory factor analysis and goodness
of fit statistics for the different models of PHQ-15. (DOC 32 kb)
Additional file 2: Figure S1. ROC curve: Using PHQ-15 for distinguishing
patients in DSM-IV/DSM-5 diagnosis. (DOC 68 kb)
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